0 Replies
SPC3649 (LNA-antimiR-122) being developed as a potential new therapy for Hepatitis C virus (HCV) infection
Ground-breaking Phase I volunteer study made possible through the success of Locked Nucleic Acid (LNA) chemistry
read more Contine Reading & Discuss→
0 Replies
(print)Banebrydende lægemiddelforsøg i Danmark
SPC3649 (LNA-antimiR-122) bliver udviklet som potentiel ny behandling af Hepatitis C virus (HCV) infektion
LNA-teknologiens succes fører til banebrydende fase I forsøg med raske frivillige
read more Contine Reading & Discuss→
0 Replies
BOULDER, Colo.–(BUSINESS WIRE)–Miragen Therapeutics, Inc., a biopharmaceutical company focused on the discovery and development of breakthrough therapies for cardiovascular and muscle disease based on microRNA biology, today announced the completion of an $8 million equity placement. The Series A financing is being co-led by founding investors Atlas Venture and Boulder... Contine Reading & Discuss→
